{"id":19189,"date":"2024-09-16T17:34:22","date_gmt":"2024-09-16T20:34:22","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/"},"modified":"2024-09-16T17:34:22","modified_gmt":"2024-09-16T20:34:22","slug":"fortitude-301-tumores-solidos","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/","title":{"rendered":"Fortitude &#8211; 301 \u2013 Tumores S\u00f3lidos"},"content":{"rendered":"<p><span data-contrast=\"auto\">Bemarituzumabe em tumores s\u00f3lidos com superexpress\u00e3o de FGFR2b.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">&nbsp;<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Popula\u00e7\u00e3o: <\/span><\/b><span data-contrast=\"auto\">Diagn\u00f3stico histologicamente ou citologicamente confirmado de tumor s\u00f3lido com superexpress\u00e3o de FGFR2b e doen\u00e7a recidivante\/refrat\u00e1ria irressec\u00e1vel e\/ou metast\u00e1tica. Pr\u00e9-triagem para testagem central de superexpress\u00e3o de FGFR2b, por imuno-histoqu\u00edmica. Doen\u00e7a mensur\u00e1vel por Recist 1.1. Pelo menos 1 regime terap\u00eautico padr\u00e3o anterior no contexto avan\u00e7ado\/metast\u00e1tico.&nbsp;<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">&nbsp;<\/span><\/p>\n<p><span data-contrast=\"auto\">Coortes abertas em <\/span><span data-contrast=\"auto\">12\/09\/2024<\/span><span data-contrast=\"auto\">: Adenocarcinoma pulmonar \u00e0 <\/span><span data-contrast=\"auto\">&gt;<\/span><span data-contrast=\"auto\"> 1 linha de terapia.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">&nbsp;<\/span><\/p>\n<p><span class=\"TextRun SCXW78310617 BCX0\" lang=\"PT-BR\" xml:lang=\"PT-BR\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW78310617 BCX0\" data-ccp-parastyle=\"x_xmsonormal\" data-ccp-parastyle-defn=\"{&quot;ObjectId&quot;:&quot;bcd369f4-e7bf-4b47-a319-106d6cebb5ee|10&quot;,&quot;ClassId&quot;:1073872969,&quot;Properties&quot;:[201342446,&quot;1&quot;,201342447,&quot;5&quot;,201342448,&quot;1&quot;,201342449,&quot;1&quot;,469777841,&quot;Calibri&quot;,469777842,&quot;Calibri&quot;,469777843,&quot;Aptos&quot;,469777844,&quot;Calibri&quot;,201341986,&quot;1&quot;,469769226,&quot;Calibri&quot;,268442635,&quot;22&quot;,335559704,&quot;1025&quot;,335559705,&quot;1046&quot;,335551547,&quot;1046&quot;,335559740,&quot;240&quot;,201341983,&quot;0&quot;,335559739,&quot;0&quot;,469775450,&quot;x_xmsonormal&quot;,201340122,&quot;2&quot;,134233614,&quot;true&quot;,469778129,&quot;xxmsonormal&quot;,335572020,&quot;1&quot;,469778324,&quot;Normal&quot;]}\">Clinical <\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW78310617 BCX0\" data-ccp-parastyle=\"x_xmsonormal\">Trials<\/span><span class=\"NormalTextRun SCXW78310617 BCX0\" data-ccp-parastyle=\"x_xmsonormal\">: <\/span><\/span><span class=\"TextRun SCXW78310617 BCX0\" lang=\"PT-BR\" xml:lang=\"PT-BR\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW78310617 BCX0\" data-ccp-parastyle=\"x_xmsonormal\">NCT05325866<\/span><\/span><span class=\"EOP SCXW78310617 BCX0\" data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">&nbsp;<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bemarituzumabe em tumores s\u00f3lidos com superexpress\u00e3o de FGFR2b.&nbsp; Popula\u00e7\u00e3o: Diagn\u00f3stico histologicamente ou citologicamente confirmado de tumor s\u00f3lido com superexpress\u00e3o de FGFR2b e doen\u00e7a recidivante\/refrat\u00e1ria irressec\u00e1vel e\/ou metast\u00e1tica. Pr\u00e9-triagem para testagem central de superexpress\u00e3o de FGFR2b, por imuno-histoqu\u00edmica. Doen\u00e7a mensur\u00e1vel por Recist 1.1. Pelo menos 1 regime terap\u00eautico padr\u00e3o anterior no contexto avan\u00e7ado\/metast\u00e1tico.&nbsp;&nbsp; Coortes abertas em [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19189","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fortitude - 301 \u2013 Tumores S\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fortitude - 301 \u2013 Tumores S\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Bemarituzumabe em tumores s\u00f3lidos com superexpress\u00e3o de FGFR2b.&nbsp; Popula\u00e7\u00e3o: Diagn\u00f3stico histologicamente ou citologicamente confirmado de tumor s\u00f3lido com superexpress\u00e3o de FGFR2b e doen\u00e7a recidivante\/refrat\u00e1ria irressec\u00e1vel e\/ou metast\u00e1tica. Pr\u00e9-triagem para testagem central de superexpress\u00e3o de FGFR2b, por imuno-histoqu\u00edmica. Doen\u00e7a mensur\u00e1vel por Recist 1.1. Pelo menos 1 regime terap\u00eautico padr\u00e3o anterior no contexto avan\u00e7ado\/metast\u00e1tico.&nbsp;&nbsp; Coortes abertas em [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/fortitude-301-tumores-solidos\\\/\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/fortitude-301-tumores-solidos\\\/\",\"name\":\"Fortitude - 301 \u2013 Tumores S\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2024-09-16T20:34:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/fortitude-301-tumores-solidos\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/fortitude-301-tumores-solidos\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/fortitude-301-tumores-solidos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Fortitude &#8211; 301 \u2013 Tumores S\u00f3lidos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fortitude - 301 \u2013 Tumores S\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/","og_locale":"pt_BR","og_type":"article","og_title":"Fortitude - 301 \u2013 Tumores S\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Bemarituzumabe em tumores s\u00f3lidos com superexpress\u00e3o de FGFR2b.&nbsp; Popula\u00e7\u00e3o: Diagn\u00f3stico histologicamente ou citologicamente confirmado de tumor s\u00f3lido com superexpress\u00e3o de FGFR2b e doen\u00e7a recidivante\/refrat\u00e1ria irressec\u00e1vel e\/ou metast\u00e1tica. Pr\u00e9-triagem para testagem central de superexpress\u00e3o de FGFR2b, por imuno-histoqu\u00edmica. Doen\u00e7a mensur\u00e1vel por Recist 1.1. Pelo menos 1 regime terap\u00eautico padr\u00e3o anterior no contexto avan\u00e7ado\/metast\u00e1tico.&nbsp;&nbsp; Coortes abertas em [&hellip;]","og_url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/","url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/","name":"Fortitude - 301 \u2013 Tumores S\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2024-09-16T20:34:22+00:00","breadcrumb":{"@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/fortitude-301-tumores-solidos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"Fortitude &#8211; 301 \u2013 Tumores S\u00f3lidos"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}